DLA Piper advises Retension Pharmaceuticals on initial public offering

DLA Piper advised Retension Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, on its US$45 million initial public offering.

Retension intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to complete the Phase 2b clinical trial of RTN-001 in uncontrolled hypertension and advance preparations for a planned Phase 3 trial.

The DLA Piper deal team was led by Partner Era Anagnosti, Senior Counsel Mitchell Marder, and Partner Andrew Gilbert, with support from lawyers across the firm’s capital solutions, life sciences, and biotechnology practices, including Partners Gina Lee, Rita Patel, Christopher Mikson, and James McGraw, Of Counsel Amanda Maki, Associates Daniel Rosenberg, Drew Calamaro, and Tamara Lentini, and Of Counsel Atul Jain.

DLA Piper enables issuers and underwriters to execute complex securities transactions throughout the world. We offer tactical approaches to financings across equity and debt capital markets, alternative public offerings (de-SPACs, reverse mergers, and direct listings), and other transformative corporate transactions. Lawyers in our Corporate Governance practice act as outside corporate and securities counsel to a wide range of reporting companies by guiding clients through securities offerings and nuanced disclosure, governance, and compliance matters under SEC, Nasdaq, and NYSE rules and regulations. Boards of directors turn to us to navigate complex transactions, special investigations, and challenging risk oversight matters. Please visit Capital Markets and Public Company Advisory and Market Edge.